首页> 美国卫生研究院文献>Contemporary Oncology >Current concepts in diagnosis and treatment of chronic lymphocytic leukemia
【2h】

Current concepts in diagnosis and treatment of chronic lymphocytic leukemia

机译:慢性淋巴细胞白血病的诊治现状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed type of leukemia in Western Europe and North America, and represents about 30% of all leukemias in adults. Chronic lymphocytic leukemia is a disease of the elderly, who are often in poorer general health and burdened with multiple comorbidities. These factors affect the decision making when choosing an appropriate method of treatment.In recent years there has been significant progress in the treatment of chronic lymphocytic leukemia, first due to the introduction of immunochemotherapy with monoclonal antibodies and latterly small molecules, like tyrosine kinase inhibitors targeting B-cell receptor signaling. This article discusses the current diagnostic principles, the most important prognostic factors and therapeutic options, available in first-line treatment and in refractory/resistant disease, including high-risk CLL, both for patients with good and those with poor performance status. It also presents important novel molecules which have been evaluated in clinical trials.
机译:慢性淋巴细胞性白血病(CLL)是西欧和北美最常被诊断为白血病的类型,约占成年人所有白血病的30%。慢性淋巴细胞性白血病是老年人的疾病,老年人的整体健康状况通常较差,并患有多种合并症。这些因素影响了选择合适的治疗方法的决策。近年来,在慢性淋巴细胞性白血病的治疗方面取得了重大进展,首先是由于引入了单克隆抗体和后来的小分子免疫疗法,如靶向酪氨酸激酶抑制剂B细胞受体信号传导。本文讨论一线治疗和难治性/耐药性疾病(包括高危CLL)的当前诊断原则,最重要的预后因素和治疗选择,适用于表现良好和表现较差的患者。它还提出了重要的新型分子,这些分子已经在临床试验中进行了评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号